
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
Argenx has demonstrated impressive financial growth, with Vyvgart revenues reaching $790 million in Q1 2025, reflecting a 98% year-over-year increase, and $949 million in Q2 2025, a 97% increase year-over-year, driven by rising adoption in generalized myasthenia gravis (gMG) and expanding traction in chronic inflammatory demyelinating polyneuropathy (CIDP). The approval of the pre-filled syringe (PFS) format significantly enhanced growth, with approximately 1,000 PFS prescribers reported and 150 new prescribers entering the market, indicating strong potential for continued expansion. Furthermore, ongoing label expansion opportunities and positive trial results from the Phase Ib DOK7-CMS study bolster the company's innovative pipeline, enhancing the outlook for future revenue growth from both existing and new indications.
Bears say
Argenx faces significant risks that contribute to a negative outlook for its stock, primarily due to concerns over lower-than-expected growth in sales of its lead product, Vyvgart. The company is also currently navigating ongoing clinical trials for efgartigimod and empasiprubart, which could be adversely affected by unforeseen safety signals or competitive pressures. Additionally, broader macroeconomic factors such as currency fluctuations, inflation, and potential shipping risks pose further challenges to Argenx’s operational stability and profitability.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares